All Updates

All Updates

icon
Filter
Partnerships
Atomwise and Sanofi enter into USD 1.2 billion AI deal
AI Drug Discovery
Aug 17, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Aug 17, 2022

Atomwise and Sanofi enter into USD 1.2 billion AI deal

Partnerships

  • California-based AI drug discovery company Atomwise has entered into a strategic multi-target research collaboration with French pharmaceutical company Sanofi to accelerate the development of novel therapeutics across various disease areas. 

  • Under the terms of the partnership, Atomwise will receive an upfront payment of USD 20 million and more than USD 1 billion potentially in milestone payments and tiered royalties.

  • The partnership will leverage Atomwise’s AI-powered drug discovery platform AtomNet which facilitates the screening of over 3 trillion synthesizable compounds to discover and develop lead compounds for up to five novel drug targets exclusive to Sanofi.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.